UniProt P52333 · PDB · AlphaFold · Substrate: JAK3tide · Clone: aa 781-1124
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 100.0% | 0.0% | 78.64 | 0.500 |
| 2 | Ponatinib | 99.3% | 0.7% | 78.23 | 0.534 |
| 3 | Ruxolitinib | 99.2% | 0.8% | 98.25 | 0.592 |
| 4 | Canertinib | 98.9% | 1.1% | 96.49 | 0.671 |
| 5 | Ibrutinib | 98.6% | 1.4% | 94.74 | 0.723 |
| 6 | Tofacitinib | 98.2% | 1.8% | 99.25 | 0.684 |
| 7 | Pralsetinib | 98.1% | 1.9% | 93.43 | 0.643 |
| 8 | Lazertinib | 97.7% | 2.3% | 97.47 | 0.674 |
| 9 | Osimertinib | 97.5% | 2.5% | 97.24 | 0.733 |
| 10 | Upadacitinib | 97.5% | 2.5% | 97.98 | 0.663 |
| 11 | Mobocertinib | 97.2% | 2.8% | 97.22 | 0.757 |
| 12 | Baricitinib | 97.0% | 3.0% | 97.99 | 0.616 |
| 13 | Repotrectinib | 96.2% | 3.8% | 84.21 | 0.608 |
| 14 | Nintedanib | 95.2% | 4.8% | 90.23 | 0.608 |
| 15 | Neratinib | 95.2% | 4.8% | 93.18 | 0.597 |
| 16 | Brigatinib | 94.8% | 5.2% | 82.96 | 0.513 |
| 17 | Pacritinib | 94.6% | 5.4% | 88.64 | 0.452 |
| 18 | Dacomitinib | 94.4% | 5.6% | 97.99 | 0.664 |
| 19 | Defactinib | 88.6% | 11.4% | 92.68 | 0.450 |
| 20 | Crizotinib | 80.5% | 19.5% | 91.39 | 0.581 |
Paralog block
JAK1, JAK2, JAK3
EMT expression
- Mesenchymal log2(TPM+1): 0.57
- Epithelial log2(TPM+1): 0.67
- Fold change: -0.10
- Status: No significant change
Selectivity landscape vs inhibition on JAK3
Each point is one of the 92 approved drugs; color = inhibition % on JAK3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…